Epstein-Barr virus-specific cytotoxic T lymphocyte precursors (EBV-CTLp) after tabelecleucel correlates with response & survival in rituximab relapsing or refractory EBV posttransplant lymphoproliferative disease (PTLD)

Autor: Prockop, S., Shen, R.R., Guzman-Becerra, N., Sun, Y., Forozan, F., Doubrovina, E., O'Reilly, R.J., Li, X., Hiremath, M., Gamelin, L., Navarro, W., Aftab, B.T.
Zdroj: In Cytotherapy May 2020 22(5) Supplement:S135-S135
Databáze: ScienceDirect